Trial Profile
Erlotinib Prevention of Oral Cancer (EPOC).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Mouth neoplasm
- Focus Therapeutic Use
- Acronyms EPOC
- 10 Jan 2019 Status changed from active, no longer recruiting to completed.
- 25 Sep 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.